Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Central Drugs Standard Control Organization (CDSCO) has invited stakeholder comments on the use of brand name extensions by pharmaceutical companies. The consultation follows concerns that different drugs marketed under the same established brand name may mislead consumers and create confusion regarding therapeutic use. Comments are invited until 17 July 2026.
Source: short-url.cc/1yKJk

2. India’s Madras High Court held that consignments imported as “waste paper” were in fact used plastic bottles, street sweepings, food waste making their import into India illegal under the Customs Act and Hazardous Waste Rules. The Court rejected the importers’ request to send the waste to Dubai, ruling that “re-export” means returning the waste to the country of origin, not to a third country chosen by the importer. The Court further condemned the practice of developed countries shifting hazardous waste to developing nations as “waste colonialism,” which undermines the environmental justice and threatens public health and ecological security. The Court refused permission to process or dispose of waste within India, to avoid becoming a “disposal destination” for foreign waste. The petitions were dismissed, the waste was ordered to be returned to the exporting countries within 60 days, and costs were imposed on the petitioners.
Source: short-url.cc/1yKL6

3. India’s Pune Municipal Corporation (PMC) has issued show-cause notices to private hospitals for non-compliance with the Bombay Nursing Homes Registration Act, 1949, including the failure to display treatment charges and patients’ rights. PMC has directed the hospitals to rectify the identified deficiencies within the prescribed timeline. The enforcement action follows inspections conducted as part of routine compliance monitoring and in response to public complaints.
Source: short-url.cc/1tdPE

4. The Indian working group on access to medicines and treatments has urged the central government to revise the National List of Essential Medicines (NLEM) by including newer cancer medicines and monoclonal antibodies. The group states that the current NLEM does not reflect the World Health Organization (WHO) model list of essential medicines.
Source: short-url.cc/1tdQ0

5. The Food Safety and Standards Authority of India has issued show cause notices to multiple food business operators for allegedly misleading claims, including the use of terms such as “fresh,” “healthy,” “natural,” “organic,” and “vegan.” The regulator has reiterated that such claims must strictly comply with the applicable labelling and advertising regulations.
Source: short-url.cc/1tdQe

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s Maharashtra’s Food and Drug Administration has reportedly issued a public warning against the use of three cosmetic products after laboratory testing detected excessive levels of mercury and lead, rendering them non-compliant with prescribed safety standards. The regulator has advised consumers to avoid using the affected products and has initiated appropriate regulatory action to prevent their sale and distribution. The move underscores the FDA’s continued efforts to safeguard public health by enforcing quality and safety standards for cosmetics.
Source: short-url.cc/1yGXL

2. Food Safety and Standards Authority of India has reportedly issued notices to energy drink brands for their misleading claims of “energy drink on product branding and labelling”. The FSSAI further states that the Food Category System under the Food Safety and Standards Regulations is not intended for product naming or labelling purposes.
Source: short-url.cc/1taa0

3. The Indian Pharmaceutical Association (IPA) has urged the ministry of health and family welfare (MoHFW) to remove AYUSH and Homeopathy provisions from the National Pharmacy Commission Bill, 2026. The association contended that the proposed bill should remain confined to the regulation of modern pharmacy education and practice, stating that the inclusion of traditional systems of medicine could dilute the existing regulatory framework for pharmaceutical sciences.
Source: short-url.cc/1yGXT

4. The Maharashtra Government has introduced the Maharashtra Clinical Establishments (Registration and Regulation) Bill, 2026, to create a comprehensive regulatory framework for clinical establishments. Replacing the Bombay Nursing Homes Registration Act, 1949, the Bill mandates registration, prescribes minimum standards, strengthens patient rights, promotes fee transparency and establishes oversight and enforcement mechanisms.
Source: short-url.cc/1taab

5. The Jharkhand High Court has held that bhang does not fall within the definition of “cannabis (hemp)” under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The Court observed that the statutory definition covers charas, ganja, and specified cannabis preparations, but does not include bhang prepared from cannabis leaves. Accordingly, the Court ruled that the possession or sale of bhang, by itself, does not attract the penal provisions of the NDPS Act, reaffirming the distinction drawn under the statutory framework.
Source: short-url.cc/1taah

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The District Consumer Disputes Redressal Commission-II, Chandigarh passed an Order in favour of the consumer for automatically levying a service charge and without obtaining the consent of the consumer; further, the opposite party refused to remove the said charge upon objection. The opposite party did not appear in the Consumer Court, hence, an ex-parte Order was passed. The opposite party was directed to refund ₹129 collected towards service charge and pay a lump-sum compensation of ₹5,000 towards harassment and litigation expenses within 45 days of receipt of the order.
Source: short-url.cc/1ymfE

2. India’s finance ministry has extended the customs duty exemption on imports of specified petrochemical products used in pharmaceutical manufacturing such as chemicals, plastics, textiles, packaging, and automotive manufacturing in view of the continuing global supply disruptions. The extension is intended to ensure the uninterrupted availability of essential raw materials, support domestic pharmaceutical production, and help mitigate input cost pressures.
Source: short-url.cc/1ymfK

3. India’s Central Consumer Protection Authority (CCPA) has imposed a ₹1 lakh penalty on a major beverages manufacturer for making a misleading “100% tender coconut water” claim. The authority held that the product’s labelling and advertising had the potential to mislead consumers regarding its composition, constituting a misleading advertisement and unfair trade practices under the consumer protection Act, 2019. The authority directed the company to discontinue the impugned advertisements and imposed a monetary penalty.
Source: short-url.cc/1sR6o

4. The Indian Multi-Disciplinary Committee of experts advised the National Pharmaceutical Pricing Authority to fix ceiling prices for intravenous fluids with advanced safety packaging at fifteen percent above existing regulated prices. If accepted, the proposal would encourage adoption of safer packaging technologies while ensuring these essential medicines remain subject to price regulation.
Source: short-url.cc/1sR6v

5. The Central Pollution Control Board (CPCB) has issued a notice directing registered battery waste recyclers to upload GST e-invoices for the sale of recovered key battery metals and metal compounds on the Battery Waste EPR Portal for EPR Certificate generation. EPR Certificates generated on the basis of non-GST e-invoices after 30 June 2026 will not be considered valid and may constitute non-compliance under the Battery Waste Management Rules, 2022.
Source: short-url.cc/1ymg3

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES 19 June

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. Maharashtra Food and Drug Administration (FDA) has directed the recall of a Schedule H prescription cough and cold medication manufactured by a leading pharmaceutical company following concerns over its public advertisement. As advertisements of Schedule H drugs are prohibited, the action highlights continued regulatory scrutiny of promotional practices for prescription medicines.
Source: short-url.cc/1sRrA

2. India plans to establish Centres of Excellence to tackle diabetes-related wounds within 2–3 years. Backed by substantial investments, these centres will integrate advanced imaging, AI-enabled monitoring, and multidisciplinary care to reduce complications like foot ulcers and amputations. These centres will also offer multiple qualified health specialists from various areas for wounds.
Source: short-url.cc/1sRrF

3. The Ministry of Health and Family Welfare has notified the amendment to the Surrogacy rules, introducing a framework for the renewal of surrogacy clinic registrations under the Surrogacy (Regulation) Act, 2021. The amendments prescribe the procedure, timelines, inspection requirements, and fees for renewal applications, provide for the utilisation of registration fees by appropriate authorities, and make renewed registrations valid for a further period of three years.
Source: short-url.cc/1ymC2

4. India’s central food authority, Food Safety and Standards Authority of India (FSSAI) has reportedly directed Food Business Operators (FBOs) to ensure that only corrosion-resistant knives and cutting tools are used in food handling, processing, preparation, and packaging activities. FSSAI has emphasized that food-contact materials and equipment must be maintained in a hygienic condition and be made of suitable materials that do not compromise food safety. Food businesses have been advised to review their operational practices and replace non-compliant equipment to ensure adherence to applicable food safety and hygiene requirements. The advisory is aimed at minimizing the risk of physical and chemical contamination arising from rusted or deteriorating equipment coming into contact with food products.
Source: short-url.cc/1ymCb

5. The Ministry of Health and Family Welfare has notified the Assisted Reproductive Technology (Regulation) Amendment Rules, 2026. The amendment inserts Rules 7A and 8A, introducing a formal renewal framework for registration of Assisted Reproductive Technology clinics and banks. It prescribes renewal application procedures, a 60-day pre-expiry filing timeline, renewal fees, and review processes, while clarifying the utilization of registration fees. Renewed registrations will remain valid for five years.
Source: short-url.cc/1sRsz

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The National Pharmaceutical Pricing Authority has increased the ceiling prices of Anti-Tetanus Immunoglobulin 250 International Units and 500 International Units injections by 50 percent exercising its extraordinary powers. The revision follows concerns over rising production costs and aims to ensure continued availability of these essential life-saving medicines.
Source: short-url.cc/1ymqX

2. India’s central food authority, FSSAI, has reportedly issued show-cause notices to eight food companies in India. One such notice was issued for deceptive branding. This Notice was issued because a brand used the claim “plant-based vegan” on the packaging which was not approved under FSSAI license obtained. Such claims have higher chances of misleading the consumers by using marketing tactics to create false impressions of the brand.
Source: short-url.cc/1ymr2

3. India’s central food authority, FSSAI, has reportedly advised Food Business Operators (FBOs) to immediately discontinue the use of metallic pins, staples, and wires in food packaging materials, citing potential risks of physical contamination and consumer injury. The regulator has urged businesses to review their packaging processes and adopt safer alternatives such as food-grade adhesives, tapes, or other secure packaging methods that do not compromise food safety. The advisory forms part of FSSAI’s ongoing efforts to strengthen food safety practices and reduce the risk of foreign matter contamination across the food supply chain.
Source: short-url.cc/1sRhw

4. The Central Drugs Standard Control Organisation (CDSCO) mandates that all manufacturers and importers of hair colour cosmetics strictly adhere to the Cosmetics Rules, 2020, and applicable Bureau of Indian Standards (BIS). To safeguard public health, stakeholders must ensure absolute compliance with statutory labelling requirements, ingredient restrictions, and mandatory caution statements. Furthermore, any alterations to a product’s composition, quality specifications, or label must be formally reported to the appropriate Central or State Licensing Authority.
Source: short-url.cc/1sRhD

5. The National Pharmaceutical Pricing Authority (NPPA) has revised upward the ceiling prices of BCG, Measles Rubella and Measles vaccines pursuant to a review order. The change reflects the Department of Pharmaceuticals’ view that the 17.1% monopoly reduction should not apply to vaccines, supporting continued vaccine availability.
Source: short-url.cc/1ymqX

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Central Drugs Standard Control Organization has directed state regulators to strengthen enforcement against the use of Chloramphenicol and Nitrofurans in food-producing animals. The move follows continued detection of these substances in export consignments, leading to international rejections and raising concerns over regulatory compliance and export competitiveness.
Source: shortlink.uk/1wKBT

2. The Food Safety and Standards Authority of India (FSSAI) has notified the Food Safety and Standards (Prohibition and Restrictions on Sales) Amendment Regulations, 2026, which came into force upon publication in the Official Gazette on 23 May 2026. Through the amendment, FSSAI has omitted clause (8) of sub-regulation 2.3.14 of the Food Safety and Standards (Prohibition and Restrictions on Sales) Regulations, 2011, following consideration of stakeholder comments received on the draft regulations issued in October 2024. The amendment formally revises the existing regulatory framework governing restrictions on the sale of specified food products under the Food Safety and Standards Act, 2006.
Source: shortlink.uk/1wKCp

3. The US FDA has launched a safety study of the abortion pill, also called mifepristone, potentially enabling new restrictions on its distribution and use. The FDA has further said for mifepristone to be safe and effective. Officials say the review is already underway and science based. The study will analyse existing data and could influence abortion access policies. Abortion right was legalised through the Supreme Court’s 2022 ruling which overturned Roe v. Wade.
Source: shortlink.uk/1rjC6

4. A pharmaceutical manufacturer has received a Warning Letter from the United States Food and Drug Administration (USFDA) concerning its formulation manufacturing facility in Baddi, Himachal Pradesh. The regulatory action was issued following a review of records submitted under the US Federal Food, Drug, and Cosmetic Act and is not linked to any on-site inspection of the facility. The observations relate to the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements. The company has stated that the Warning Letter is not expected to impact ongoing operations or product supplies from the facility and has committed to undertaking the necessary corrective actions and responding to the USFDA within the prescribed timelines. The facility was last inspected by the USFDA in August 2025 and subsequently received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification.
Source: shortlink.uk/1wKCB

5. Hospitals across India are reportedly facing shortages of key chemotherapy drugs, including cisplatin and carboplatin, disrupting cancer treatment schedules and forcing patients to search for alternative supplies. The shortage has been linked to supply chain constraints and rising input costs, raising concerns about continuity of care and treatment outcomes.
Source: shortlink.uk/1wKCH

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s central food authority, FSSAI has notified the Food Safety and Standards (Vegan Foods) Amendment Regulations, 2026 which introduces revised official logo specifications for approved vegan food products, replacing the 2022 framework. Mandating the updated logo on all approved packages, the new requirements will take effect from July 1, 2027, offering businesses a transition period for packaging updates.
Source: shortlink.uk/1qVzx

2. The Department of Consumer Affairs has amended the Legal Metrology (Packaged Commodities) Rules, 2011, allowing importers to make mandatory declarations at bonded warehouses of Tier-2 and Tier-3 Authorised Economic Operators. The amendments also require disclosure of the director responsible for violations, mandate annual updates of registration details, and clarify that registration certificates will remain valid until cancelled.
Source: shortlink.uk/1qVzz

3. The Employees’ State Insurance Corporation (ESIC) has launched a centralized online patient feedback system across its hospitals and dispensaries to strengthen patient-centric healthcare delivery and improve service quality. The digital platform enables beneficiaries to submit feedback on various aspects of healthcare services, including medical care, staff behaviour, cleanliness, waiting time, and overall patient experience. The initiative aims to facilitate real-time monitoring of patient satisfaction, enhance accountability, and support timely resolution of grievances.
Source: shortlink.uk/1wkLy

4. The Delhi High Court has allowed pharmaceutical company to continue selling its cancer drug Bevatas, overturning an earlier order. The court ruled that Bevatas and Bevetex are sufficiently distinct in appearance, pronunciation and use, making consumer confusion unlikely and permitting continued sales.
Source: shortlink.uk/1wkLD

5. The National Medical Commission has issued an advisory directing all medical colleges to mandatorily implement safe injection practices, including exclusive use of sterile single-use needles and syringes, strict infection prevention measures, proper biomedical waste disposal, periodic staff training, and prompt reporting of needle-stick injuries to prevent the transmission of blood-borne infections such as HIV, Hepatitis B (HBV), and Hepatitis C (HCV).
Source: shortlink.uk/1wkLF

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. India’s central health ministry has notified the revised fees for testing or analysis for drugs, vaccines, and AYUSH medicines given under Schedules B and B(1) of the Drugs Rules, 1945. The revised fees will be applicable in three months post-publication in official gazette. The fees shall automatically increase by 5% annually. For the tests that are not listed in the Schedule, charges will be determined by the Director or the Government Analyst of the Laboratory or institute. This update will focus on strengthening India’s testing infrastructure while increasing compliance expenses for manufacturers.
Source: shortlink.uk/1qPI3

2. The Delhi High Court dismissed the appeal challenging exclusive rights in the mark“REDDY” for pharmaceutical goods, affirming cancellation of a conflicting registration and restraining its continued use. The ruling reinforces the importance of acquired distinctiveness, market reputation, and consumer protection in trademark enforcement within regulated industries.
Source: shortlink.uk/1weId

3. This official corrigendum by India’s NPPA, dated May 27, 2026, corrects the manufacturer and brand names under serial number 4 of Table-B in its previous Ringer Lactate ceiling price order (S.O. 1584(E)) (p. 2). The manufacturer is now M/s Fresenius Kabi India, with brands ‘Freeflex bags’ and ‘Eurohead bottle’ (p. 2).
Source: shortlink.uk/1qPID

4. National Pharmaceutical Pricing Authority may reportedly refer the methodology for fixing ceiling prices of intravenous (IV) fluids to its Multi-Disciplinary Committee (MDC) of experts after identifying inconsistencies in pricing across formulations and special-feature packaging. The review will improve transparency and consistency in the pricing of IV fluids while addressing concerns over packaging-related pricing variations.
Source: shortlink.uk/1weIH

5. The Food Safety and Standards Authority of India (FSSAI) has sought an explanation from a leading quick commerce platform following a consumer complaint alleging illness after consuming curd purchased through the platform. The regulator has reportedly requested a detailed Action Taken Report (ATR) and sought information regarding food safety compliance, while noting multiple recent complaints relating to allegedly spoiled, unhygienic, or damaged food products sold through the platform’s marketplace sellers. The development underscores increasing regulatory scrutiny of food safety obligations in the e-commerce and quick commerce sector, particularly concerning platform accountability for products sold by third-party sellers.
Source: shortlink.uk/1weIQ

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

1. The Department of Consumer Affairs met with major edible oil industry associations on 20 May 2026 to discuss standardizing pack sizes between 200 ml and 20 litres. The initiative aims to enhance consumer protection, ensure transparency in pricing, and prevent misleading packaging. Associations representing 90% of the sector supported the proposal, recommending exemptions for minor oils and packs below 200 ml, with a three month transition period for implementation.
Source: shortlink.uk/1vJbr

2. The Central Drugs Standard Control Organisation (CDSCO) has clarified that Form CT-16 applications for import of Reference Listed Drugs (RLDs) or Investigational Medicinal Products (IMPs) for export-oriented BA-BE studies may be submitted on a standalone basis through the NSWS portal. The clarification addresses operational issues due to lack of system linkage between CT-05 prior intimation applications and CT-16 applications on the SUGAM portal.
Source: shortlink.uk/1vJby

3. The Karnataka Pharma Retailers & Distributors Organization (KPRDO) has urged the government to immediately curb misleading advertisements and aggressive promotional practices relating to prescription, life-saving, and scheduled medicines, particularly across social media platforms. The organisation has also called for the creation of a specialised enforcement team and digital monitoring mechanism to address regulatory violations under the Drugs & Cosmetics Act and the Drugs & Magic Remedies Act. The recommendations could also intensify scrutiny on pharmaceutical advertising, online promotional activities, pharmacy practices, and trade compliance across the healthcare and pharma sectors.
Source: shortlink.uk/1vJbD

4. India’s central food authority has notified the Food Safety and Standards (Contaminants, Toxins and Residues) Amendment Regulations, 2026, revising contaminant limits across pulses, edible oils, seafood, oilseeds, and nutmeg containing products. Updated standards cover heavy metals, aflatoxins, veterinary drug residues, and inorganic arsenic in fish oils, effective from 1 December 2026. Food businesses, seafood exporters, and nutraceutical companies must review and strengthen quality assurance systems, testing protocols, and sourcing controls to ensure compliance.
Source: FSSAI Gazette Notification, Food Safety and Standards (Contaminants, Toxins and Residues) Amendment Regulations, 2026
Source: shortlink.uk/1vJbI

5. India’s Himachal Pradesh High Court has ruled that criminal liability cannot automatically be imposed on all directors or partners of a pharmaceutical company without specific averments establishing individual roles in business conduct. The judgment tightens procedural and evidentiary requirements for regulators prosecuting ‘Not of Standard Quality’ and spurious drug cases, potentially making enforcement actions under the Drugs and Cosmetics Act more legally complex for drug regulators and enforcement agencies.
Source: shortlink.uk/1vMU6

Posted on

TOP 5 HEALTH LAWS AND POLICY UPDATES

Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.

The Ministry of Health and Family Welfare has placed Pregabalin under Schedule H1 of the Drugs Rules, 1945, amid concerns over its rising misuse for sedative, euphoric, and dissociative effects, particularly among youth. The move seeks to strengthen regulatory control by restricting over-the-counter access and ensuring sale only against valid prescriptions with stricter monitoring and record-keeping requirements.
Source: shortlink.uk/1vI8d

India’s Madras High Court ruled that a mother need not undergo DNA testing to donate a kidney to her son when official records establish their biological relationship. The court set aside the transplant approval rejection and directed authorities to permit the donation immediately. This humanitarian interpretation reinforces that documentation standards should prioritise life saving procedures over rigid procedural requirements, potentially influencing future authorization committee decisions on donor recipient relationships.
Source: shortlink.uk/1vI8z

India’s central food authority is moving towards a centralised food surveillance system deploying third party agencies for sample collection, centralised laboratory testing, and digital alerts for faster regulatory action. The framework requires 50% of samples from organised supply chains. The shift signals a technology driven overhaul of food safety governance, raising compliance and traceability expectations for manufacturers, retailers, and supply chain operators.
Source: shortlink.uk/1vI8l

4. Global pharmaceutical companies are increasingly shifting high-value clinical research, regulatory, pharmacovigilance, and innovation-led functions to India as the country evolves from a low-cost outsourcing destination into a strategic global research and development hub. The shift could accelerate investments in clinical research infrastructure, advanced therapies, AI-enabled drug development, and specialised talent while strengthening India’s competitiveness as a global life sciences and biotech hub.
Source: shortlink.uk/1qk9u

5. The Competition Commission of India (CCI) has rejected allegations of monopoly and excessive pricing against 12 private hospitals in Delhi, ruling that higher prices alone do not prove abuse of dominance. The regulator found hospitals operated within competition norms, allowed external procurement, and charged within MRP, dismissing decade-long complaints.
Source: shortlink.uk/1vI8q